Treatment of atherosclerotic renovascular disease

dc.contributorUniversidade Estadual Paulista (UNESP)
dc.creatordos Santos Silva, Vanessa
dc.creatorFranco, Roberto Jorge da Silva
dc.creatorMartin, Luis Cuadrado
dc.date2014-05-27T11:23:32Z
dc.date2016-10-25T18:25:28Z
dc.date2014-05-27T11:23:32Z
dc.date2016-10-25T18:25:28Z
dc.date2008-05-01
dc.date.accessioned2017-04-06T01:30:47Z
dc.date.available2017-04-06T01:30:47Z
dc.identifierCurrent Hypertension Reviews, v. 4, n. 2, p. 114-120, 2008.
dc.identifier1573-4021
dc.identifierhttp://hdl.handle.net/11449/70404
dc.identifierhttp://acervodigital.unesp.br/handle/11449/70404
dc.identifier10.2174/157340208784245875
dc.identifier2-s2.0-48249113788
dc.identifierhttp://dx.doi.org/10.2174/157340208784245875
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/891508
dc.descriptionTreatment of atherosclerotic renovascular disease is controversial and revascularization is not a beneficial approach to all patients. Conditions as progressive deterioration of renal function, refractory hypertension or accelerated cardiovascular disease, especially recurrent pulmonary edema, could profit from renal angioplasty with stent placement. Surgical revascularization is a good option for patients who will need concomitant surgical corrections of abdominal aortic lesions. Treatment of all other patients must be individualized. Medical therapy is indicated for all patients with atherosclerotic renovascular disease. Observational studies pointed out to the beneficial effect of controlling blood pressure (<130/80 mm Hg), glucose and lipids profile, lifestyle modifications, specific use of platelet antiaggregant therapy, Angiotensin Conversion Enzyme Inhibitors (ACEI) and statins. All others cardiovascular risk factors must be controlled. The evaluation and management of other systemic atherosclerotic vascular lesions is important, especially coronary, carotid and abdominal aortic. This paper presents a review of evidences to rationale the atherosclerotic renovascular disease treatment. © 2008 Bentham Science Publishers Ltd.
dc.languageeng
dc.relationCurrent Hypertension Reviews
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAtherosclerosis
dc.subjectMedical therapy
dc.subjectRenal angioplasty
dc.subjectRenal artery stenosis
dc.subjectRenovascular
dc.subjectTreatment
dc.subjectangiotensin receptor antagonist
dc.subjectantithrombocytic agent
dc.subjectbeta adrenergic receptor blocking agent
dc.subjectcalcium channel blocking agent
dc.subjectcerivastatin
dc.subjectdipeptidyl carboxypeptidase inhibitor
dc.subjectglucose
dc.subjecthydroxymethylglutaryl coenzyme A reductase inhibitor
dc.subjectlipid
dc.subjectsimvastatin
dc.subjectthiazide diuretic agent
dc.subjectvasodilator agent
dc.subjectabdominal aorta
dc.subjectacute kidney failure
dc.subjectangioplasty
dc.subjectaorta disease
dc.subjectatherosclerosis
dc.subjectblood pressure regulation
dc.subjectcardiovascular disease
dc.subjectcardiovascular risk
dc.subjectcarotid artery disease
dc.subjectclinical feature
dc.subjectclinical protocol
dc.subjectclinical trial
dc.subjectcoronary artery disease
dc.subjectdeterioration
dc.subjectdisease model
dc.subjectdrug use
dc.subjectdrug withdrawal
dc.subjectfollow up
dc.subjecthuman
dc.subjecthypertension
dc.subjectkidney function
dc.subjectlifestyle modification
dc.subjectlung edema
dc.subjectmetabolic regulation
dc.subjectnonhuman
dc.subjectpathogenesis
dc.subjectpercutaneous transluminal angioplasty
dc.subjectpriority journal
dc.subjectrecurrent disease
dc.subjectrenal artery
dc.subjectrenovascular disease
dc.subjectrevascularization
dc.subjectreview
dc.subjectstent
dc.subjecttreatment indication
dc.titleTreatment of atherosclerotic renovascular disease
dc.typeOtro


Este ítem pertenece a la siguiente institución